Document:

EXHIBIT 10.2

            AUDITORS' REPORT TO THE MEMBERS OF ASTRAZENECA PLC

We have audited the accompanying consolidated group balance sheets of
AstraZeneca Plc and subsidiaries ('AstraZeneca') as of December 31, 2002 and
2001 and the related consolidated group profit and loss accounts, consolidated
group statements of total recognised gains and losses and consolidated
statements of group cash flow for each of the years in the three-year period
ended December 31, 2002. These consolidated financial statements are the
responsibility of AstraZeneca's management. Our responsibility is to express an
opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audit provides a reasonable basis for our opinion.

In our opinion, the aforementioned consolidated financial statements present
fairly, in all material respects, the financial position of AstraZeneca as of
December 31, 2002 and 2001, and the results of their operations and their cash
flows for each of the years in the three-year period ended December 31, 2002,
in conformity with generally accepted accounting principles in the United
Kingdom.

As more fully described in the "Basis of Consolidation and Presentation of
Finanical Information" note to the consolidated financial statements,
AstraZeneca has adopted FRS No. 19 Deferred Tax in the year ended December 31,
2002. Consequently, AstraZeneca's consolidated financial statements as of
December 31, 2001 and the two year period ended December 31, 2001 referred to
above have been restated.

Generally accepted accounting principles in the United Kingdom vary in certain
significant respects from accounting principles generally accepted in the United
States of America. Application of generally accepted accounting principles in
the United States of America would have affected results of operations for each
of the years in the three-year period ended December 31, 2002 and shareholders'
equity as of December 31, 2002 and 2001, to the extent summarised in the
"Additional Information for US Investors" section of the consolidated financial
statements on pages 113 to 122 of the consolidated financial statements. As
discussed in the "Additional Information for US Investors" section of the
consolidated financial statements, effective January 1, 2002, AstraZeneca
fully adopted the provisions of Statement of Financial Accounting Standards
("SFAS") No. 142, "Goodwill and Other Intangible Assets".

/s/  KPMG AUDIT PLC

KPMG Audit Plc
Chartered Accountants
Registered Auditor
8 Salisbury Square
London
EC4Y 8BB

January 30, 2003EXHIBIT 10.3

                       CONSENT OF INDEPENDENT ACCOUNTANTS

The Board of Directors
AstraZeneca Plc

We hereby consent to the incorporation by reference in the registration
statement (No. 33-83774) on Form F-3 and the registration statements (No.
333-09060, No. 333-09062, No. 333-65362, No. 33-65366, No. 333-12310, No.
333-12426, No. 333-12428, No. 333-13328 and No. 333-13918) on Form S-8 of
AstraZeneca Plc of our report dated January 30, 2003 with respect to the
consolidated group balance sheets of AstraZeneca Plc and subsidiaries as of
December 31, 2002 and 2001 and the related consolidated group profit and loss
accounts, consolidated group statements of total recognised gains and losses and
consolidated statements of group cash flow for each of the years in the
three-year period ended December 31, 2002 which report appears in the 2002
Annual Report on Form 20-F of AstraZeneca Plc.

/s/  KPMG AUDIT PLC

KPMG Audit Plc, London

March 25, 2003EXHIBIT 10.5

                                                                             ims

12th March 2003

Adrian Kemp
AstraZeneca plc
Legal & Secretary's Department
Room 3.10, Stanhope Gate
15 Stanhope Gate
London W1K 1LN

Dear Adrian,

IMS Data Disclosure for Annual Report

In connection with AstraZeneca's anticipated filing of certain registration
statements IMS HEALTH hereby authorizes you to refer to IMS HEALTH and Certain
pharmaceutical industry data derived by IMS HEALTH, as identified on the pages
annexed hereto as Exhibit A, a selection of pages from AstraZeneca's Annual
Report for the fiscal year ended 2002 (the "Annual Report", which is
incorporated by reference in the registration statement No. 33-83774 on Form
F-3, for AstraZencca group and Zeneca Wilmington Inc., and in the registration
statements No. 333-09060, No. 333-09062, No. 333-65362, No. 33-65366, No.
333-12310, No. 333-12426, No. 333-12428, No. 333-13328 and No. 333-13918 on Form
S-8 for AstraZeneca Plc. A copy of the relevant pages of the Annual Report has
been provided to IMS HEALTH.

Our authorization is subject to your acknowledgment and agreement that:

1)   IMS HEALTH has not been provided with a full copy of the draft Annual
     Report but only a very limited number of pages from the documents as
     indicated above;

2)   IMS HEALTH has not undertaken an independent review of the information
     disclosed in the Annual Report other than to discuss our observations as
     to the accuracy of the information relating to IMS HEALTH and certain
     pharmaceutical industry data derived by IMS HEALTH; and

3)   AstraZeneca accepts full responsibility for the disclosure of all
     information and data, including that relating to IMS HEALTH, set forth in
     the Annual Report as filed with the SEC and agrees to indemnify IMS HEALTH
     from any third party claims that may arise therefrom.

Please indicate your agreement to the foregoing by signing in the space
indicated below. Our authorisation will not become effective until accepted and
agreed by AstraZeneca.

Very truly yours,

/s/ Paul Jenner

Paul Jenner, Director Communications and Marketing Services
For and on behalf of IMS HEALTH

IMS Health                  Tel +44(0)20 7393-5000     IMS A.G. registered &
7 Harewood Avenue           Fax+44(0)20 7393-5900      incorporated with
London NWI 6JB                                         limited liability in
United Kingdom                                         Zug, Switzerland,
                                                       registered as a branch
                                                       in England, Ref. No.
                                                       BR 1589, Swiss address
                                                       Dorfplatz 4, 6330 CHAM.

<PAGE>

                                                                             ims

ACCEPTED AND AGREED
THIS 20TH DAY OF MARCH 2003:

AstraZeneca

By:  /s/ Adrian C N Kemp
   ------------------------------------

Name:  Adrian C N Kemp
     ----------------------------------

Title:  Assistant Secretary
     ----------------------------------

Appendix A: Selection of pages in Annual Report

IMS Health                  Tel +44(0)20 7393-5000     IMS A.G. registered &
7 Harewood Avenue           Fax+44(0)20 7393-5900      incorporated with
London NWI 6JB                                         limited liability in
United Kingdom                                         Zug, Switzerland,
                                                       registered as a branch
                                                       in England, Ref. No.
                                                       BR 1589, Swiss address
                                                       Dorfplatz 4, 6330 CHAM.
<PAGE>

                                                                       EXHIBIT A

Annotations from Final version Feb 20 2003 IMS.pdf

Page 3
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:45:12
Nexium NRX and TRX US

Page 7
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date; 2003-02-20 13:46:21
Seroquel US (N5A1);
Atacand global (Excl Japan) C9C+C9D

Page 10
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:46:59
US market size and growth

Page 12
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:47:55
Global market (32 countries) growth:
Selected markets share and growth

Annotation 2: Label: BaseInstaller: Date: 2003-02-20 13:48:50
Top5 and top10 corporations share of global

Page 13
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:49:18
A2B2 market size

Annotation 2; Label: BaseInstaller; Date: 2003-02-20 13:51:06
US - Nexium overtake Losec RX;
Nexium global and US share of A2B2

Annotation 3; Label: BaseInstaller; Date: 2003-02-20 13:51:23
Losec US and global share

Page 14
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:56:14
CV treatment: C, B1, B2, A8A, A10

Annotation 2; Label; BaseInstaller; Date: 2003-02-20 13:57:05
Atacand, C9C+C9D
31 countries

Annotation 3; Label: BaseInstaller; Date: 2003-02-20 13:58:05
Atacand C9C+C9D

Annotation 4; Label: BaseInstaller; Date: 2003-02-20 14:01:35
Intprd Betaloc

Annotation 5; Label: BaseInstaller; Date: 2003-02-20 14:02:59
Zestril family: Zestril, Zestoretic, (C9A+C9B)

Annotation 6; Label: BaseInstaller; Date: 2003-02-20 14:04:12

<PAGE>

 Statin market: ClOAl

Page 15
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:07:10
Cancer therapy market: L1+L2

Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:09:09
Casodex; Antiandrogens L2B2

Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:09:59
Arimidex; Aromatase inhib. L2B3

Page 16
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:17:54
Thinfection world market is an AstraZeneca estimation

Page 17
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:19:16
Total R-class

Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:20:45
Symbicort: R3f1

Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:22:49
Pulmicort Respules. US NPA data

Annotation 4; Label: BaseInstaller; Date: 2003-02-20 14:23:21
Oxis. R3A3

Annotation 5; Label: BaseInstaller; Date: 2003-02-20 14:24:40
Rhinocort Aqua. RX % of R1A1

Page 18
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:27:15
CNS therapies: N2C, N3A, N4A, N5, N6, N7

Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:53:09
Seroquel, Antipsychotic market N5A

Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:54:03
Zomig. Share of N2C

Page 19
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:57:32
Pain control Market, AZ defined:
M1A, M2A, Narcotics, Weak Opioids, Simple analgetics, N2C, Neurontin (60% US,
30% EU and 10% RoW)

Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:58:17
Anaesthetic market: N1

Annotation 3; Label: BaseInstaller; Date: 2003-02-20 15:19:59

<PAGE>

Diprivan, N1A

Page 20
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 15:22:02
Nexium. Share of A2B2 TRX

Annotation 2; Label: BaseInstaller; Date: 2003-02-20 15:36:51
Zestril TRX share of C9A

Annotation 3; Label: BaseInstaller; Date: 2003-02-20 15:38:51
Toprol-XI TRX share of C7A

Annotation 4; Label: BaseInstaller; Date: 2003-02-20 15:40:52
Casodex: L2B2

Page 21
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20  15:45:37
Oncology = L1+L2

Annotation 2; Label: BaseInstaller; Date: 2003-02-20  15:47:42
All countries: Nexium share of A2B2;
Symbicort share of R3F1

Page 22
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20  15:49:18
Casodex share of L2B2

Annotation 2; Label: BaseInstaller; Date: 2003-02-20  15:49:52
Seroquel share of N5A1

Page 24
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20  16:28:05
Nexium share of A2B2

Page 25
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20  16:26:28
Symbicort share of R3F1

Page 26
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20  16:29:18
Seroquel share of N5A1

Annotation 2; Label: BaseInstaller; Date: 2003-02-20  16:30:06
Zomig share of N2C1

Annotation 1; Label: BaseInstaller; Date: 2003-02-20  16:55:57
Pages 34-40 not attached in this document.
Pages 40-43 from last year's Financial Review, according to US requirements.
Rest of Annual report no market data included.

<PAGE>

Page 27
--------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20  16:41:37
Pages 56 to 113 not attached in this document/EJ

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}]]